The US has launched a trade probe into Germany's pharmaceutical pricing, alleging it unfairly burdens American commerce and forces the US to shoulder a disproportionate share of global drug development costs. This investigation, under Section 301, could lead to new tariffs on Germany. Officials cite concerns that German policies suppress prices for innovative medicines, impacting research funding and potentially affecting American patients.

America has started a trade probe into Germany's plan to cut pharmaceutical spending. U.S. Trade Representative Jamieson Greer stated the investigation will determine if Germany's…

The US Trade Representative said a new probe would determine if Germany was a underpaying for pharmaceuticals.